# Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

> **NCT06717269** · PHASE1 · RECRUITING · sponsor: **Nurix Therapeutics, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** NX-5948
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT06717269
- **Lead sponsor:** Nurix Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2026-04
- **Final completion:** 2026-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717269, "Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06717269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*